Treatment and outcome of children and adolescents with N-methyl-d-aspartate receptor encephalitis
- 19 May 2015
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 262 (8) , 1859-1866
Abstract
The objective of this study is to describe the treatment and outcome of children and adolescents with N-methyl-d-aspartate receptor (NMDA-R) encephalitis. A retrospective study of children and adolescents with NMDA-R encephalitis was performed by the French Paraneoplastic Neurological Syndrome Reference Center between January 1, 2007 and December 31, 2012. The modified Rankin scale (mRS) was used to assess outcome. Thirty-six children and adolescents with NMDA-R encephalitis were studied. All of the patients received first-line immunotherapy (corticosteroids, intravenous immunoglobulins or plasma exchange), and 81 % received second-line immunotherapy (rituximab or cyclophosphamide). Median time between first-line and second-line treatment was 26 days. During the first 24 months, 30 of 36 patients (83 %) achieved a good outcome (mRS ≤ 2) and 20 of 36 patients (56 %) achieved complete recovery (mRS = 0). Median time to good outcome and to complete recovery was 6 and 24 months, respectively. Three patients (8 %) relapsed, one patient died. In multivariate analysis, age >12 years was a predictor of good outcome and initial mRS ≤ 3 was a predictor of complete recovery. Despite a higher rate of patients who received second-line immunotherapy, the outcome of the patients in the present series was very similar to the outcome reported in previous series. The present study highlights the need for clinical trials to determine the optimal treatment of NMDA-R encephalitis.Keywords
This publication has 24 references indexed in Scilit:
- Childhood Stiff-Person Syndrome Improved with RituximabCase Reports in Neurology, 2012
- Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitisNeurology, 2011
- Response of patients with refractory myasthenia gravis to rituximab: a retrospective studyTherapeutic Advances in Neurological Disorders, 2011
- Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitisThe Lancet Neurology, 2011
- In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunctionOrphanet Journal of Rare Diseases, 2010
- N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexesBrain, 2010
- Practical considerations on the use of rituximab in autoimmune neurological disordersTherapeutic Advances in Neurological Disorders, 2010
- Anti–N‐methyl‐D‐aspartate receptor (NMDAR) encephalitis in children and adolescentsAnnals of Neurology, 2009
- Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodiesThe Lancet Neurology, 2008
- Paraneoplastic anti–N‐methyl‐D‐aspartate receptor encephalitis associated with ovarian teratomaAnnals of Neurology, 2007